Abstract
Naïve T cells can commit to effector [T helper 1 (Th1), Th2 and Th17] or regulatory lineages. Skewing of responses toward inflammatory Th1, Th2 or Th17 pathways and away from regulatory T-cell pathways might be responsible for the initiation and progress of immune-mediated diseases. Based on recent data, we propose that interleukin-21 (IL-21), a cytokine produced by activated CD4+ T cells, induces the development of Th17 cells, blocks the differentiation of transforming growth factor-beta1-induced regulatory T cells and renders CD4+ T cells resistant to the suppressive effects of regulatory T cells, thereby playing a major role in pathogenic T-cell responses.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibody Formation / drug effects
-
B-Lymphocytes / immunology
-
B-Lymphocytes / metabolism
-
CD8-Positive T-Lymphocytes
-
Cell Differentiation / drug effects
-
Cell Differentiation / immunology
-
Cell Proliferation / drug effects
-
Humans
-
Immune System Diseases / therapy
-
Inflammation
-
Interleukins* / immunology
-
Interleukins* / metabolism
-
Interleukins* / pharmacology
-
Lymphocyte Activation / drug effects
-
Lymphocyte Activation / immunology*
-
Th1 Cells / immunology*
-
Th1 Cells / metabolism
-
Th2 Cells / immunology*
-
Th2 Cells / metabolism
-
Transforming Growth Factor beta1 / antagonists & inhibitors*
Substances
-
Interleukins
-
Transforming Growth Factor beta1
-
interleukin-21